• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Am J Physiol Lung Cell Mol Physiol . The SARS-CoV-2 Spike Protein Subunit 1 induces COVID-19-like acute lung injury in Κ18-hACE2 transgenic mice and

tetano

Editor, Senior Moderator
Am J Physiol Lung Cell Mol Physiol


. 2021 Jun 22.
doi: 10.1152/ajplung.00223.2021. Online ahead of print.
The SARS-CoV-2 Spike Protein Subunit 1 induces COVID-19-like acute lung injury in Κ18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells


Ruben Colunga Biancatelli[SUP] 1 [/SUP], Pavel Solopov[SUP] 1 [/SUP], Elizabeth R Sharlow[SUP] 2 [/SUP], John S Lazo[SUP] 2 [/SUP], Paul Ellis Marik[SUP] 3 [/SUP], John D Catravas[SUP] 1 3 4 [/SUP]



Affiliations

Abstract

Acute lung injury (ALI) leading to acute respiratory distress syndrome is the major cause of COVID-19 lethality. Cell entry of SARS-CoV-2 occurs via the interaction between its surface Spike protein (SP) and angiotensin converting enzyme-2 (ACE2). It is unknown if the viral Spike protein alone is capable of altering lung vascular permeability in the lungs or producing lung injury in vivo. To that end, we intratracheally instilled the S1 subunit of SARS-CoV-2 Spike protein (S1SP) in K18-hACE2 transgenic mice that overexpress human ACE2 and examined signs of COVID-19 - associated lung injury 72 hours later. Controls included K18-hACE2 mice that received saline or the intact SP and wild-type (WT) mice that received S1SP. K18-hACE2 mice instilled with S1SP exhibited a decline in body weight, dramatically increased white blood cell and protein concentrations in bronchoalveolar lavage fluid (BALF), upregulation of multiple inflammatory cytokines in BALF and serum, histological evidence of lung injury and activation of STAT3 and NFκB pathways in the lung. K18-hACE2 mice that received either saline or SP exhibited little or no evidence of lung injury. WT mice that received S1SP exhibited a milder form of COVID-19 symptoms, compared to K18-hACE2 mice. Further, S1SP, but not SP, decreased cultured human pulmonary microvascular transendothelial resistance and barrier function. This is the first demonstration of a COVID-19-like response by an essential virus encoded protein by SARS-CoV-2 in vivo. This model of COVID-19-induced ALI may assist in the investigation of new therapeutic approaches for the management of COVID-19 and other coronaviruses.

Keywords: Acute lung injury; COVID-19; Cytokine storm; SARS-CoV-2; Spike protein.
 
Back
Top Bottom